(Q27698001)

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Tea Pemovska

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Gretchen Repasky

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Olli-Pekka Kallioniemi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Kimmo Porkka

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Eric Johnson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Mika Kontro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Jeffrey Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Peter Wells

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Ciarán N Cronin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Michele McTigue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Brion W Murray

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

5 March 2015

0 references

published in

Nature

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

519

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

7541

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

102-105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Activation of tyrosine kinases by mutation of the gatekeeper threonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Clinical pharmacology of axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Phasercrystallographic software

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Features and development of Coot

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Refinement of macromolecular structures by the maximum-likelihood method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

PHENIX: a comprehensive Python-based system for macromolecular structure solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE14119

Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring

21 January 2018

1 reference

12 December 2020

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

12 December 2020

Targeted treatments in advanced renal cell carcinoma: focus on axitinib.

1 reference

12 December 2020

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

1 reference

12 December 2020

FDA halts then allows sales of Ariad's leukemia medication

1 reference

12 December 2020

Identifiers

DOI

10.1038/NATURE14119

2 references

Consolidated OpenCitations Corpus – April 2017

5007661

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 June 2020

1004586276

0 references

5007661

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

5007661

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686603%20AND%20SRC:MED&resulttype=core&format=json